Burden of Co-Infection: A Cost Analysis of Human Immunodeficiency Virus in a Commercially Insured Hepatitis C Virus Population
Abstract Introduction In patients with hepatitis C virus (HCV), human immunodeficiency virus (HIV) represents a major cause of morbidity and economic burden. Economic evaluations in HIV-HCV typically focus on government-sponsored insurance plans rather than a commercially insured cohort. This study...
Main Authors: | T. Joseph Mattingly, Neha S. Pandit, Eberechukwu Onukwugha |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2019-03-01
|
Series: | Infectious Diseases and Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1007/s40121-019-0240-7 |
Similar Items
-
Drug costs in context: assessing drug costs in cost-of-illness analyses
by: T Joseph Mattingly II, et al.
Published: (2022-07-01) -
Economic Burden of Hepatitis B at Different Stages of the Disease: A Systematic Review Study
by: Shima Bordbar, et al.
Published: (2024-10-01) -
Current estimates of the economic burden of blindness and visual impairment in India: A cost of illness study
by: Sunny Mannava, et al.
Published: (2022-01-01) -
Cost of healthcare services in patients with chronic rhinosinusitis from the public hospital perspective: a retrospective prevalence-based costing approach
by: Trung Quang Vo
Published: (2019-03-01) -
Burden of illness imposed by severe sepsis in Switzerland
by: A Schmid, et al.
Published: (2004-02-01)